IceCure Medical Ltd. - Ordinary Shares (ICCM)

Frequently Asked Questions About IceCure Medical Ltd. - Ordinary Shares (ICCM)

How can investors learn more about IceCure Medical?

Investors can learn more about IceCure Medical by visiting the company's official website, reviewing investor presentations, and accessing SEC filings. Additionally, they can follow company updates and announcements through press releases and investor relations communications.

How does IceCure Medical approach R&D?

IceCure Medical places a strong emphasis on research and development (R&D) to innovate and improve its cryoablation technologies. The company invests significantly in R&D to enhance the efficacy and safety of its products, ensuring they meet the needs of both physicians and patients.

How does IceCure Medical ensure compliance with regulatory standards?

IceCure Medical ensures compliance with regulatory standards by implementing rigorous quality management systems and protocols throughout all stages of product development and manufacturing. The company actively engages with regulatory agencies to meet both local and international requirements.

How does IceCure Medical ensure product safety and efficacy?

IceCure Medical is committed to ensuring product safety and efficacy through rigorous clinical trials and regulatory compliance. The company adheres to the highest standards set by regulatory authorities, including obtaining necessary approvals before bringing products to market.

How does IceCure Medical plan to expand its market presence?

IceCure Medical aims to expand its market presence by increasing the adoption of its cryoablation technology in hospitals and outpatient clinics globally. The company focuses on educating healthcare professionals about the benefits of cryoablation and establishing strategic distribution channels.

Is IceCure Medical Ltd. publicly traded?

Yes, IceCure Medical Ltd. is publicly traded on the Nasdaq under the ticker symbol ICCM. The company went public to raise capital to support its research, development, and commercialization efforts for its innovative medical technologies.

What are IceCure's key products?

IceCure Medical’s key products include the ProSense™ device, which is designed for the treatment of breast tumors using cryoablation. They also offer the Cryoablation System for various other tumor types, enhancing minimally invasive cancer treatment options for patients.

What are the potential benefits of using cryoablation?

Cryoablation offers several potential benefits, including minimally invasive treatment, reduced recovery time, and preservation of healthy tissue. It also has the potential to be performed on an outpatient basis, which can significantly enhance patient comfort and convenience.

What clinical trials is IceCure Medical currently conducting?

IceCure Medical is actively conducting clinical trials to evaluate the safety and efficacy of its cryoablation technology across various tumor types. These trials are essential for obtaining regulatory approvals and providing evidence for the clinical benefits of their products.

What collaborations or partnerships does IceCure Medical have?

IceCure Medical collaborates with various healthcare institutions, researchers, and oncologists to advance its clinical studies and improve treatment protocols. These partnerships help facilitate the adoption of their cryoablation technology across different medical communities.

What does IceCure Medical Ltd. do?

IceCure Medical Ltd. is a biotechnology company that specializes in developing innovative medical devices for the treatment of tumors through a technique called cryoablation. Their primary focus is on breast cancer and other tumor types, leveraging ice technology to destroy cancer cells without the need for invasive surgical procedures.

What financial information is available for IceCure Medical?

As a publicly traded company, IceCure Medical provides financial information through regular filings with the SEC, including quarterly and annual reports. This information includes details on revenue, expenses, research and development investments, and overall financial health.

What future plans does IceCure Medical have for product development?

IceCure Medical plans to continue expanding its product line by developing new cryoablation devices for additional indications and tumor types. The company is also focusing on enhancing its existing technologies and exploring innovative solutions to improve patient outcomes in oncological treatment.

What is cryoablation?

Cryoablation is a medical procedure that uses extreme temperatures to freeze and destroy abnormal tissue, such as tumors. By applying localized cold to targeted areas, the procedure aims to minimize damage to surrounding healthy tissue while effectively eliminating cancerous cells.

What is the ProSense™ device?

The ProSense™ device is a cryoablation system specifically designed for the treatment of benign and malignant tumors. It allows for precise control over the freezing process, ensuring effective tumor destruction with minimal disruption to surrounding tissue.

What is the target audience for IceCure Medical's products?

The target audience for IceCure Medical's products includes oncologists, surgical specialists, and healthcare institutions that treat cancer patients. The company aims to provide these stakeholders with effective, minimally invasive treatment options for tumors.

What markets does IceCure Medical target?

IceCure Medical primarily targets markets in oncology, focusing on treatments for breast cancer and various other tumor types. The company aims to expand its reach into both established markets and emerging regions to maximize the impact of its technologies.

Where is IceCure Medical Ltd. headquartered?

IceCure Medical Ltd. is headquartered in Israel. The company operates from its main office, where it is involved in research and development activities, regulatory affairs, and business operations related to its innovative cryoablation technologies.

Who are the key executives at IceCure Medical?

IceCure Medical is led by a team of experienced executives with backgrounds in medical device development, business, and oncology. Key executives typically include a CEO, COO, and other leadership positions focused on operational and strategic management.

What is the current price of IceCure Medical Ltd. - Ordinary Shares?

The current price of IceCure Medical Ltd. - Ordinary Shares is 1.150

When was IceCure Medical Ltd. - Ordinary Shares last traded?

The last trade of IceCure Medical Ltd. - Ordinary Shares was at 1:17 pm EDT on April 4th, 2025